Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Dec 2;152(22):1526-1537.
doi: 10.1161/CIRCULATIONAHA.125.076557. Epub 2025 Aug 29.

Peri-Interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Noninferiority Trial

Affiliations
Multicenter Study

Peri-Interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Noninferiority Trial

Hans-Josef Feistritzer et al. Circulation. .

Abstract

Background: Minimalist treatment strategies for transcatheter aortic valve implantation have been widely adopted because of continued procedural evolution, but large randomized trials are lacking. The DOUBLE-CHOICE trial (Randomized Study Comparing Both Latest Generation Self-Expanding Valves and a Minimalist Approach Versus Standard of Care in Transcatheter Aortic Valve Implantation) evaluated the safety and efficacy of a minimalist approach (MA) compared with the standard of care (SoC) for transfemoral transcatheter aortic valve implantation.

Methods: In this investigator-initiated, 2×2 factorial, open-label, randomized, multicenter, noninferiority trial, patients with symptomatic aortic stenosis were included at 10 German sites. Patients were randomly assigned to the MA, including isolated local anesthesia, versus the SoC using conscious sedation. The primary end point was a composite of all-cause mortality, vascular and bleeding complications, infection requiring antibiotic therapy, and neurological events at 30 days. The noninferiority of the MA compared with the SoC was tested in the intention-to-treat population with an absolute noninferiority margin of -6% at an α level of 0.05.

Results: Between July 11, 2022, and January 14, 2025, 752 patients were randomly assigned to the MA (n=377) and SoC (n=375). The median age was 83 (interquartile range, 79-86) years, 439 (58.5%) patients were women, and the median Society of Thoracic Surgeons risk score was 4.6% (interquartile range, 2.9-8.0). The primary end point occurred in 80 (22.9%) of 350 patients in the MA group and in 91 (25.8%) of 353 patients in the SoC group (rate difference, 2.9%; lower boundary of the 1-sided 95% CI, -2.4%; P for noninferiority=0.003; 2-sided 95% CI, -3.4 to 9.3; P for difference=0.37). Patient-reported anxiety and stress levels during the procedure were higher in the MA group.

Conclusions: The MA including isolated local anesthesia was noninferior to the SoC with conscious sedation, highlighting the safety and efficacy of the MA for transcatheter aortic valve implantation. The burden of intraprocedural pain and discomfort is potentially higher in the MA group.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05036018.

Keywords: anesthesia; aortic stenosis; fast-track; minimalist approach; transcatheter aortic valve implantation; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

Dr Rudolph discloses that her hospital received speaker honoraria or consultancy fees from Boston Scientific, Medtronic, JenaValve, and Edwards Lifesciences. Dr Kim received personal fees from Abbott, Anteris, Boston Scientific, Edwards Lifesciences, Emboline, HID Imaging, JenaValve, Meril Life Sciences, and P & F and an institutional grant from Boston Scientific. Dr Borger discloses that his hospital receives speaker honoraria or consulting fees on his behalf from Edwards Lifesciences, Medtronic, Abbott, and Artivion. Dr Abdel-Wahab discloses that his hospital received speaker honoraria or consultancy fees on his behalf from Boston Scientific, Medtronic, and Edwards Lifesciences.

Comment in

Associated data

LinkOut - more resources